Crinetics About 2020

News

Crinetics Presents New Posters on ACTH Antagonist and SST5 Agonist Programs at ENDO Online 2020

SAN DIEGO – June 8, 2020 – Crinetics Pharmaceutials, Inc. (Nasdaq: CRNX), Presents New Posters on ACTH Antagonist and SST5 Agonist Programs at ENDO Online 2020.

Discovery and Identification of Late Stage, Selective Nonpeptide ACTH Antagonists for the Treatment
of Cushing’s Disease, Ectopic ACTH Secreting Tumors, and Congenital Adrenal Hyperplasia

Ana K. Kusnetzow, Sangdon Han, Melissa A. Fowler, Jon Athanacio, Greg Reinhart, Elizabeth Rico-Bautista, Sun Hee Kim, Michael Johns, Taylor A. Kredel, Agnes Antwan, Oleg Tsivkovski, Julie Nguyen, Christine Staley, Hannah Tan, Rosalia de Necochea-Campion, Jacob Hawver Pachter, Rosa Luo, Stacy Markison, Ajay Madan, Yun Fei Zhu, R. Scott Struthers, Stephen F. Betz. ENDO Online 2020. June 8-22, 2020.

Discovery and Identification of Late Stage, Selective Nonpeptide Somatostatin Subtype 5 (SST5)
Agonists for the Treatment of Hyperinsulinemic Hypoglycemia

Melissa A. Fowler, Jian Zhao, Emmanuel Sturchler, Elizabeth Rico-Bautista, Rosalia de Necochea-Campion, Jon Athanacio, Taylor A. Kredel, Agnes Antwan, Michael Johns, Oleg Tsivkoski, Shimiao Wang, Rosa Luo, Ana K. Kusnetzow, Ajay Madan, R. Scott Struthers, Stacy Markison, Yun Fei Zhu, Stephen F. Betz. ENDO Online 2020. June 8-22, 2020.


Crinetics Pharmaceuticals Appoints Adriana Cabré, MBA, as Vice President of
Human Resources

SAN DIEGO – May 27, 2020 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Adriana Cabré, MBA, as Vice President of Human Resources.

“We are pleased to welcome Adriana to the executive team to lead our Human Resource function,” said Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics. “Adriana’s broad experience across all aspects of human resources, including previously building a commercial endocrinology organization, will be highly valuable as we grow and expand our capabilities. Our employees are our most important competitive advantage and we are committed to preserving the entrepreneurial, scientifically rigorous, and inclusive culture that has underpinned our success so far. Adriana’s leadership will be critical in helping to continue to grow and nurture this high performing team as the organization matures.”

“I am excited to join the Crinetics family during such a pivotal time. Crinetics has an exceptionally talented team that is driven by its mission to bring innovative and transformative treatment options for patients with rare diseases,” said Ms. Cabré.

Ms. Cabré brings over 25 years of experience in human resources to the role, most recently serving as President of ACC People Strategies, a consulting practice she founded to provide customized human resource solutions. Prior to that, Ms. Cabré served as Chief People Officer at National University from September 2016 through September 2019. From February 2014 to May 2016, she was Senior Vice President of Human Resources at MedImpact Healthcare Systems, Inc. From 2006 to 2014, Ms. Cabré served as Senior Director and then Vice President of Human Resources at Amylin Pharmaceuticals where she helped lead the effort to build their commercial organization. She has also served as a Human Resources Director for both CooperVision and Motorola.

Ms. Cabré holds a B.A. in International Business from Duquesne University and an MBA from Nova Southeastern University.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate, paltusotine (formerly CRN00808), is an oral, selective nonpeptide somatostatin receptor type 2 biased agonist undergoing two Phase 2 clinical trials for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. Crinetics plans to advance paltusotine into a Phase 3 trial in acromegaly and a Phase 2 trial for the treatment of carcinoid syndrome associated with neuroendocrine tumors in 2021. The company is also developing an oral nonpeptide somatostatin receptor type 5 agonist for hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing’s disease, congenital adrenal hyperplasia and other diseases of excess ACTH. All of the company’s drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company. For more information, please visit www.crinetics.com.

Contacts:
Marc Wilson
Chief Financial Officer
IR@crinetics.com
(858) 450-6464

Robert H. Uhl
Westwicke Partners
robert.uhl@westwicke.com
(858) 356-5932